Obesity is having an excessive amount of body fat in relation to lean body mass that may impair health.
The primary cause is an energy imbalance between calories consumed and expended.
Treatment goals include to lose 5-10% of body weight or 0.5-1 kg (1-2 lb)/week for 6 months and regain of <3 kg in 2 years and sustained reduction of waist circumference of at least 4 cm.
Strategies are aiming for realistic goals and a multidisciplinary approach that is a combination of dietary change, physical activity and behavioral modification.
Patients who have undergone weight-loss surgery may sometimes have to return for revision, which helps improve outcomes associated with obesity, such as diabetes and hypertension, according to a meta-analysis.
Among middle-aged and older adults, sleeping poorly is related to general and abdominal obesity, short sleep duration to both sarcopaenic and general obesity, and depression to sarcopaenia, as suggested in a study.
The glucagon-like peptide-1 receptor agonist (GLP1-RA) liraglutide helps prevent and/or reverse memory function decline in obese patients with prediabetes or early type 2 diabetes mellitus (T2DM), whereas a lifestyle intervention produces improvements in attentive functions, a study has shown.
While bariatric surgery is increasingly recommended in obese teens to achieve significant, sustained weight loss and resolve comorbid diseases, a study has shown a major downside to the procedure: nutritional deficiencies, specifically in iron and vitamin B12.
Patients with type 2 diabetes mellitus (T2DM) who are overweight or obese but have high cardiorespiratory fitness (CRF)* may have a reduced risk of heart failure (HF), according to a study presented at EPI Lifestyle 2020.
At the Novartis-sponsored VERIFY Soft Launch held at Le Meridien, Kuala Lumpur, two distinguished speakers spoke on the latest updates in glucose-lowering therapy and the benefit of early treatment intensification using combination therapy (ie, vildagliptin/metformin) in the management of T2DM.